China Pharma (CPHI) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Talphera (TLPH) has outperformed China Pharma (CPHI) over the past year, losing 16.7% versus a loss of 51.8%. Over five years, TLPH leads with a -94.9% price change compared with -99.7% for CPHI. Talphera is the larger company by market cap ($56.1 million vs $41.3 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPHI | TLPH |
|---|---|---|
| Share price | $0.96 | $1.08 |
| Market cap | $41.30M | $56.06M |
| 1-day change | +12.94% | +2.86% |
| YTD return | -20.66% | -7.89% |
| 1-year return | -51.76% | -16.67% |
| 5-year return | -99.65% | -94.85% |
| EPS (TTM) | $-0.42 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.19 | $1.57 |
| 52-week low | $0.38 | $0.69 |
| Distance from 52-week high | -95.00% | -31.21% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +189.81% |
| Average volume | 5.47M | 251.66K |
| Shares outstanding | 43.02M | 51.91M |
| Employees | 215 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed CPHI by 35.1 percentage points over the past year.
About China Pharma
CPHI stock →China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China.
Healthcare · Drug Manufacturers - Specialty & Generic · 215 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
CPHI vs TLPH FAQ
Which is bigger, China Pharma or Talphera?
Talphera (TLPH) is larger, with a market capitalization of $56.06M compared with $41.30M for China Pharma (CPHI).
Which stock has performed better over the past year, CPHI or TLPH?
TLPH returned -16.67% over the past 12 months, compared with -51.76% for CPHI (price return, excluding dividends). Past performance does not predict future results.
Are China Pharma and Talphera in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.